Previous Close | 3.9500 |
Open | 3.8965 |
Bid | 3.9300 x 900 |
Ask | 4.5000 x 1200 |
Day's Range | 3.7700 - 3.8999 |
52 Week Range | 2.5500 - 5.9700 |
Volume | |
Avg. Volume | 5,316 |
Market Cap | 5.808M |
Beta (5Y Monthly) | 2.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7100 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for XBIO
Xenetic Biosciences ( NASDAQ:XBIO ) Full Year 2023 Results Key Financial Results Revenue: US$2.54m (up 49% from FY...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, ...
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a ...